HIV-1 gp120 CD4 binding site antibodies targeting HIV escape mutants
US12173052B2 · kind B2 · utility
0Cited by
11References
6Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 13, 2021 |
| Grant date | Dec 24, 2024 |
| Priority date | — |
| Expiry date | Oct 3, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16122
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) broadly neutralizing antibodies having improved potency and breadth for neutralizing a range of HIV strains. Combinations of broadly neutralizing antibodies can also improve potency over a single antibody composition.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.